Literature DB >> 7354469

The clinical progression of apparent juvenile rheumatoid arthritis to systemic lupus erythematosus.

C G Ragsdale, R E Petty, J T Cassidy, D B Sullivan.   

Abstract

Ten patients with juvenile rheumatoid arthritis (JRA) developed clinical manifestations of systemic lupus erythematosus (SLE) in 2 1/2 to 21 yr. At onset there was little to distinguish these patients from other children with JRA. Chronic arthritis developed in all and was not different from that seen in JRA. Onset of SLE followed a flare of arthritis in 8 patients, development of serositis in 5, and fever and rash in 5. LE cells and elevated DNA-binding were found in all patients, and glomerulonephritis was demonstrated in the 6 patients on whom renal biopsies were done. This group of patients may represent an important diagnostic subset of children with JRA or SLE.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7354469

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Overlapping juvenile idiopathic arthritis and systemic lupus erythematosus: a case report.

Authors:  Anna Bazsó; Krisztina Sevcic; Ilonka Orbán; Gyula Poór; Zsolt Balogh; Emese Kiss
Journal:  Rheumatol Int       Date:  2010-07-30       Impact factor: 2.631

Review 2.  Systemic lupus erythematosus in children.

Authors:  A M Rosenberg
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Systemic lupus erythematosus in childhood.

Authors:  F Caeiro; F M Michielson; R Bernstein; G R Hughes; B M Ansell
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

4.  Steroid-responsive nephrotic syndrome in a child with juvenile idiopathic arthritis.

Authors:  Flavio Bandin; Marion Merhenberger; Anne Modesto; Karine Brochard; Stéphane Decramer
Journal:  Pediatr Nephrol       Date:  2007-11-24       Impact factor: 3.714

Review 5.  Autoantibody profile in juvenile chronic arthritis.

Authors:  A M Leak
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.